Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AVA6000 |
Synonyms | |
Therapy Description |
AVA6000 consists of a doxorubicin molecule covalently linked to a dipeptide that can be hydrolyzed by fibroblast activation protein alpha (FAP), potentially leading to release of doxorubicin in the tumor microenvironment and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1815). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AVA6000 | AVA 6000|AVA-6000 | Chemotherapy - Anthracycline 13 | AVA6000 consists of a doxorubicin molecule covalently linked to a dipeptide that can be hydrolyzed by fibroblast activation protein alpha (FAP), potentially leading to release of doxorubicin in the tumor microenvironment and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1815). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |